Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» XMT-1522
XMT-1522
FDA lifts clinical hold from Mersana’s breast cancer trial
Fierce Biotech
Mon, 09/17/18 - 09:46 am
FDA
clinical trials
Mersana
antibody-drug conjugate
XMT-1522
breast cancer
Patient death prompts FDA hold on Mersana’s lead cancer ADC
Fierce Biotech
Sat, 07/21/18 - 12:14 am
Mersana
XMT-1522
antibody-drug conjugate
patient deaths
clinical trials
After billion-dollar drug deal, patient death and trial hold cripple Mersana’s shares
Endpoints
Thu, 07/19/18 - 09:49 am
Mersana
patient deaths
XMT-1522